Regenxbio Inc (RGNX)

Jul 28, 2025

How many analysts rate REGENXBIO Inc. as a “Buy”AI Powered Tips For 2025 - jammulinksnews.com

Jul 28, 2025

Jul 28, 2025

Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances in Gene Therapy and Novel Drug Approvals | DelveInsight - GlobeNewswire Inc.

Jul 28, 2025

Jul 28, 2025

What are the latest earnings results for REGENXBIO Inc.Get daily updates on promising stocks - jammulinksnews.com

Jul 28, 2025

Jul 27, 2025

What is the dividend policy of REGENXBIO Inc. stockInvest confidently with professional guidance - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

What makes REGENXBIO Inc. stock price move sharplyBuild a portfolio that stands the test of time - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

What catalysts could drive REGENXBIO Inc. stock higher in 2025Free Popular Stock Recommendations - jammulinksnews.com

Jul 27, 2025

Jul 25, 2025

What drives REGENXBIO Inc. stock priceJaw-dropping returns - PrintWeekIndia

Jul 25, 2025

Jul 24, 2025

What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey

Jul 24, 2025

Jul 23, 2025

What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional

Jul 23, 2025

Jul 23, 2025

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com

Jul 23, 2025

Jul 22, 2025

REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025

Jul 18, 2025

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance

Jul 18, 2025

Jul 18, 2025

(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 18, 2025

Jul 11, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jul 11, 2025

Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com

Jul 10, 2025

Jul 10, 2025

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News

Jul 10, 2025

Jul 09, 2025

Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com

Jul 09, 2025

Jul 08, 2025

RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail

Jul 08, 2025

Jul 08, 2025

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛

Jul 08, 2025

Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025

Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025

Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025

Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025

Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025

Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025

Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025

Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025

Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025

Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025

Jun 06, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive

Jun 06, 2025

Jun 06, 2025

RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter

Jun 06, 2025